Resources
- Global Sales of Antibody-drug Conjugates (ADCs) in 2025
- From ADC to XDC: Types of Novel Drug Conjugates
- Next-Generation PDC: Linker Design with PEG & Clinical Progress
- Oral Macrocyclic Peptides in Clinical Practice
- Review: Hydrophilic linkers in Antibody-drug Conjugates
- FDA 2025 Approvals: Innovation and Next-Gen Blockbuster Drugs
- 2026 FDA Drug Approvals: Blockbusters to Watch
- The Rise of PD-L1 ADCs: A New Paradigm in Cancer Therapy
- 9 Potential Blockbuster Drugs to be Approved in 2022
- Overview of HER2-targeted Drugs
